Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;34(7):e13146.
doi: 10.1111/jne.13146. Epub 2022 May 25.

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Simona Grozinsky-Glasberg  1 , Joseph Davar  2 , Johannes Hofland  3 , Rebecca Dobson  4 , Vikas Prasad  5 , Andreas Pascher  6 , Timm Denecke  7 , Margot E T Tesselaar  8 , Francesco Panzuto  9 , Anders Albåge  10 , Heidi M Connolly  11 , Jean-Francois Obadia  12 , Rachel Riechelmann  13 , Christos Toumpanakis  14
Affiliations

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Simona Grozinsky-Glasberg et al. J Neuroendocrinol. 2022 Jul.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Algorithm for CHD investigation in patients with CS and/or high level of 5‐HIAA. CS, carcinoid syndrome; CHD, carcinoid heart disease; 5‐HIAA, 5‐hydroxiindolic acid; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; RHF, right heart failure
FIGURE 2
FIGURE 2
Refractory carcinoid syndrome work‐up. u5‐HIAA, urinary 5‐hydroxiindolic acid; SSA, somatostatin analogues
FIGURE 3
FIGURE 3
Refractory carcinoid syndrome: proposed treatment sequence. *Aggressive CS: more than four bowel movements (BM)/day and/or more than five flushing episodes/day. **When available, and when CS‐related diarrhoea is predominant. ***Surgical debulking can be considered earlier, if possible, in highly selected cases, based on the type of liver metastasis (Type I or Type II) and weighing up severity of CHD and the impact of debulking on CHD. CS, carcinoid syndrome; CHD, carcinoid heart disease; MDT, multidisciplinary team; PRRT, peptide receptor radioligand, therapy; SSA, somatostatin analogues; u5‐HIAA, urinary 5‐hydroxiindolic acid
See this image and copyright information in PMC

References

    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995‐998. - PMC - PubMed
    1. Clement D, Ramage J, Srirajaskanthan R. Update on pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol. 2020;2020:1‐11. doi:10.1155/2020/8341426 - DOI - PMC - PubMed
    1. Ito T, Lee L, Jensen RT. Carcinoid‐syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018;25(1):22‐35. - PMC - PubMed
    1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population‐based study. Lancet Oncol. 2017;18(4):525‐534. - PMC - PubMed
    1. De Jesus T, Luis SA, Ryu JH, et al. Carcinoid Heart Disease in Patients With Bronchopulmonary Carcinoid. J Thorac Oncol. 2018;13(10):1602‐1605. - PubMed

MeSH terms

LinkOut - more resources